US House passes bill restricting contracts with Chinese biotech firms

The U.S. House of Representatives passed the Biosecure Act on September 9, 2024, with a vote of 306 to 81. The bill restricts federal contracts with Chinese biotech firms, including WuXi AppTec and BGI, citing national security concerns. It must now pass the Senate before reaching President Biden. Critics argue the bill lacks clarity on the companies' identification and may hinder competition.